CCND1 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 is altered in 6.25% of dedifferentiated chondrosarcoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 25.0% of dedifferentiated chondrosarcoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].